41 Views | 24 Downloads
Dalane W. Kitzman, MD, Kermit Glenn Phillips II Chair in Cardiovascular Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, Tel: 336-716-3274, Fax: 336-716-4995. Email: dkitzman@wakehealth.edu
In addition to partial funding for the present study from Novartis (which had no role in study conduct, data analysis, interpretation, or manuscript generation), Dr. KItzman reports the following potential financial conflicts of interest: Consultant for Abbvie, Bayer, Merck, Medtronic, Relypsa, Merck, Corvia Medical, Boehringer-Ingelheim, GSK, and Actavis, current research grant funding from Novartis, Bayer, and GSK, and stock ownership in Gilead Sciences. Dr. Upadhya has received research funding from Novarits and Corvia.
This study was funded, in part, by an investigator-initiated grant from Novartis Pharmaceuticals. However, Novartis had no role in study conduct, data analysis, interpretation, or manuscript generation.
Also funded in part by: NIH R01AG18915 and R01AG045551; The Claude D. Pepper Older Americans Independence Center of Wake Forest University NIH P30AG21332; Clinical and Translational Science Institute of Wake Forest School of Medicine NIH UL1TR001420; and the Kermit G. Phillips II Chair in Cardiovascular Medicine of Wake Forest School of Medicine.